What is ABOS's current stock price?

ABOS (Acumen Pharmaceuticals, Inc.) is currently trading at $2.42 with a market cap of $146.6M.

What sector is Acumen Pharmaceuticals, Inc. in?

Acumen Pharmaceuticals, Inc. (ABOS) operates in the Healthcare sector, specifically in the Biotechnology industry.

Is ABOS a good stock to buy?

Analysts have a Buy consensus on ABOS with a price target of $7.00. Check our detailed analysis for valuation, financials, and insider activity.

InvestLog

ABOS Acumen Pharmaceuticals, Inc.

Healthcare

$2.42-3.59%ClosedMarket Cap: $146.6M

As of 2026-05-26

Valuation

View Details

P/E (TTM)

—

PEG

—

P/B

1.81

P/S

0.00

EV/EBITDA

-1.04

DCF Value

$0.38

FCF Yield

-69.4%

Div Yield

0.0%

Margins & Returns

Gross Margin

0.0%

Operating Margin

0.0%

Net Margin

0.0%

ROE

-123.1%

ROA

-84.8%

ROIC

-96.7%

Financials

View All

Period	Revenue	Net Income	EPS
Q1 null	$0.00	$-20.7M	$—
Q4 null	$0.00	$-25.1M	$—
FY null	$0.00	$-121.3M	$—
Q3 null	$0.00	$-26.5M	$—

Analyst Ratings

View All

Consensus

Buy

Target (Consensus)

$7.00

Target (Median)

$7.00

Target Range

$7.00 - $7.00

0 Strong Buy6 Buy0 Hold0 Sell0 Strong Sell

BTIGBuy

2026-03-26

BTIGBuy

2026-01-27

B of A SecuritiesBuy

2025-11-18

B of A SecuritiesBuy

2025-08-25

Trading Activity

Insider Trades

View All

RA CAPITAL MANAGEMENT, L.P.director, 10 percent owner:

SellWed Mar 18

Meisner Derek Mofficer: Chief Legal Officer & Corp Sec

SellTue Mar 10

Meisner Derek Mofficer: Chief Legal Officer & Corp Sec

SellTue Mar 10

Meisner Derek Mofficer: Chief Legal Officer & Corp Sec

SellTue Mar 03

Meisner Derek Mofficer: Chief Legal Officer & Corp Sec

SellTue Mar 03

Company Info

Sector

Healthcare

Industry

Biotechnology

Country

Exchange

—

Beta

0.32

Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate ACU193, a humanized monoclonal antibody that is in Phase I clinical-stage to target soluble amyloid-beta oligomers. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Charlottesville, Virginia.

Peers

INO

IRD